Q
Qnovia
Pharmaceutical company whose mission is to help save lives
About Qnovia
Qnovia, Inc. is a clinical-stage pharmaceutical company focused on developing and commercializing inhaled therapeutics. Founded in 2018 by Mario Danek as Respira Technologies, the company rebranded to Qnovia in September 2022. Danek, an inventor with a background in company launches, hardware manufacturing, and FDA regulatory strategy, created the initial prototype for the company's core technology after identifying a gap in the market for more effective smoking cessation tools. The company, initially based in Los Angeles, later relocated its headquarters to Richmond, Virginia, to be closer to key partners.
The company's primary business is the development of drug-device combination products aimed at improving patient outcomes, with an initial focus on the multi-billion dollar nicotine replacement therapy (NRT) market. Qnovia is developing a prescription-based treatment for smokers who want to quit. The business model centers on gaining regulatory approval for its products and then commercializing them, targeting a patient population that has not seen significant treatment advancements in decades. Since its inception, the company has raised $50 million through several funding rounds, including a $17 million Series A in 2022 and a $16 million Series B in late 2024, with lead investors like Blue Ledge Capital, Evolution VC Partners, and Vice Ventures.
Qnovia's lead product is the RespiRx™, a portable, orientation-agnostic, vibrating mesh nebulizer. This device is designed for the deep lung delivery of pharmaceuticals. Its first application, QN-01, is a prescription nicotine inhaler intended as a smoking cessation therapy. Unlike existing NRTs such as patches or gums which deliver nicotine slowly, the RespiRx™ is engineered to provide rapid delivery upon inhalation, more effectively managing cravings and withdrawal symptoms. The system uses single-use, pre-filled cartridges, eliminating the need for cleaning and maintenance. It also features a digital display to track dosing in real-time, supporting a 12-week step-down program where the nicotine dose is gradually reduced. In October 2024, the FDA cleared Qnovia's Investigational New Drug (IND) application, allowing the company to begin Phase 1 clinical trials in the U.S. The company is simultaneously pursuing a Marketing Authorization Application (MAA) in the U.K. for an expedited path to revenue. Beyond NRT, Qnovia plans to leverage its platform for other therapeutic areas, including asthma, COPD, vaccine delivery, and pain management.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- West Hollywood, United States
- Employees
- 13
- Open positions
- None listed
- Dealroom signal
- 76.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Addiction, Hard Tech, DT and LS, science-based
- Technology
- Hardware
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Dec 2024 | $16M | $64M | Vice Ventures · Blue Ledge Capital · Gaingels · Evolution VC Partners | ↗ |
| SERIES A✓Equity / VC | Jun 2023 | $2.9M | $85M | Blue Ledge Capital · Evolution VC Partners | ↗ |
Growth signals
Latest recorded traffic for Qnovia is 130 monthly website visits, down 18.8% over the last three months. Qnovia's team grew 8.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Qnovia in the West Hollywood ecosystem
The Qnovia office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
Poseidon Asset Management
Sand Hill Angels
Gaingels
Vice Ventures
DG Ventures
Blue Ledge Capital- TCTL Capital
Evolution VC Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Qnovia on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Qnovia’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.






